^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Brain Cancer

    Related cancers:
    21h
    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca (clinicaltrials.gov)
    P1/2, N=83, Recruiting, Virginia Commonwealth University | Trial completion date: May 2027 --> Jan 2031 | Trial primary completion date: May 2026 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
    |
    RAS mutation
    |
    Nerlynx (neratinib)
    21h
    Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 (clinicaltrials.gov)
    P2, N=104, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    21h
    Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG (clinicaltrials.gov)
    P1/2, N=10, Active, not recruiting, InSightec | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    doxorubicin hydrochloride
    23h
    Window of Opportunity Study of DSP-0390 in Gliomas (clinicaltrials.gov)
    P1, N=20, Recruiting, Washington University School of Medicine | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    23h
    Two Cut-Off Values of Plethysmographic Variability Index to Guide Intraoperative Fluid Therapy on Serum Lactate in Patients Undergoing Excision of Supra-Tentorial Brain Tumors (clinicaltrials.gov)
    P=N/A, N=32, Completed, Cairo University | Trial completion date: Aug 2025 --> Feb 2026 | Initiation date: Feb 2025 --> Sep 2025 | Trial primary completion date: Aug 2025 --> Feb 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    1d
    GLIOSTELLA: A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Philogen S.p.A. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lomustine • Fibromun (onfekafusp alfa)
    1d
    ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma (clinicaltrials.gov)
    P1, N=94, Recruiting, Mayo Clinic | Trial completion date: Feb 2029 --> May 2029 | Trial primary completion date: Feb 2028 --> May 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    WSD0628
    1d
    Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing. (PubMed, Nat Biotechnol)
    We experimentally validated several actionable findings, including tepotinib to target the IRAK1/4-cholesterol pathway in glioblastoma, brigatinib to target the MARK2/3-Hippo pathway in pancreatic cancer and gilteritinib to overcome MET mutation-driven drug resistance and metastasis. To facilitate exploration of our data, we provide KIRHub, a web-based tool that allows identification of existing inhibitors of wild-type and mutated kinases to guide precision oncology.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR (Fibroblast Growth Factor Receptor) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • MARK2 (Microtubule Affinity Regulating Kinase 2)
    |
    MET mutation
    |
    Xospata (gilteritinib) • Alunbrig (brigatinib) • Tepmetko (tepotinib)
    1d
    Thr3/Ser90 phosphorylation-stabilized S100A8 regulates cholesterol metabolism in glioblastoma stem cells. (PubMed, Oncogene)
    Furthermore, ROCK1-mediated phosphorylation of S100A8 at Thr3/Ser90, which stabilized S100A8 by impairing its binding to Fbxo10 and inhibiting the subsequent ubiquitination-mediated degradation. Our study reveals the S100A8-ROS-mTORC1 axis as a cholesterol metabolic vulnerability in GSCs, providing new insights into cholesterol metabolism and highlighting novel metabolism therapeutic strategies in GBM.
    Journal
    |
    S100A8 (S100 Calcium Binding Protein A8)
    1d
    Role of the WNT signalling pathway in physiological and pathological blood-brain barrier. (PubMed, Ann Med)
    Targeted modulation of this pathway represents a promising therapeutic strategy for restoring BBB function and improving CNS drug delivery. Further mechanistic and translational studies are warranted to advance clinical applications.
    Review • Journal
    |
    SOX17 (SRY-Box Transcription Factor 17) • WNT7A (Wnt Family Member 7A) • HBP1 (HMG-Box Transcription Factor 1)
    1d
    ECE1c promotes glioblastoma invasion via the ROCK2-MYH10 axis and interaction with ACTB. (PubMed, Am J Transl Res)
    Our results indicate that ECE1c is a key regulator of GBM invasion through ROCK2 activation and interaction with ACTB. Targeting ECE1c may represent a viable therapeutic strategy for treating invasive GBM.
    Journal
    |
    CD44 (CD44 Molecule) • ECE1 (Endothelin Converting Enzyme 1)